Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 EPIDEMIOLOGY
6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT
7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS
7.1 REGULATORY SCENARIO IN THE U.S
7.2 REGULATORY SCENARIO IN AUSTRALIA
7.3 REGULATORY SCENARIO IN JAPAN
7.4 REGULATORY SCENARIO IN CHINA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE
8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER
8.1.3 IMPROVED IMAGING TECHNIQUES
8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER
8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES
8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS
8.3 OPPORTUNITIES
8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC
8.3.3 RISING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS
8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS
9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 IMAGING TEST
9.2.1 CT SCAN
9.2.2 MRI
9.2.3 PET
9.2.4 OTHERS
9.3 MOLECULAR TESTING
9.4 ELECTROENCEPHALOGRAPHY (EEG)
9.5 LUMBAR PUNCTURE
9.6 BIOPSY
9.6.1 OPEN BIOPSY
9.6.2 STEREOTACTIC BIOPSY
9.6.3 NEEDLE BIOPSY
9.6.4 NEUROENDOSCOPY
9.7 OTHERS
10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 GLIOBLASTOMA MULTIFORME
10.3 MENINGIOMAS
10.4 ASTROCYTOMAS
10.5 ACOUSTIC NEUROMA
10.6 OLIGODENDROGLIOMA
10.7 OLIGODENDROGLIOMA
10.8 OTHERS
11 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 35-65
11.3 65 AND ABOVE
11.4 BELOW 21
11.5 21-34
12 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES
12.5 AMBULATORY SURGICAL CENTERS
12.6 OTHERS
13 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 RUSSIA
13.1.7 SWITZERLAND
13.1.8 NETHERLANDS
13.1.9 TURKEY
13.1.10 BELGIUM
13.1.11 REST OF EUROPE
14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE
16.1 KONINKLIJKE PHILIPS N.V.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 CANON INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 SIEMENS HEALTHCARE GMBH
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 BD
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENTS
16.5 NIHON KOHDEN CORPORATION.
16.5.1 COMPANY SNAPSHOT
16.5.2 RECENT FINANCIALS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BIOCEPT, INC.
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 BIOMIND
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 CEREBRAL DIAGNOSTIC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 DXCOVER LIMITED
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 FONAR CORP.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 FUJIFILM CORPORATION
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 GE HEALTHCARE.
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 HITACHI, LTD.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 MINFOUND MEDICAL SYSTEMS CO.,
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENT
16.15 NANTOMICS.
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT
16.16 NEUSOFT CORPORATION
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 SEQUOIA HEALTHCARE.
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT
16.18 STERNMED GMBH
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENT
16.19 THERMO FISHER SCIENTIFIC INC.
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TIME MEDICAL HOLDING.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 18 EUROPE 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 EUROPE 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 21 EUROPE 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 23 EUROPE HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 30 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 31 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 35 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 36 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 37 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 38 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 39 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 40 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 41 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 42 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 43 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 44 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 45 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 46 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 47 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 48 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 49 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 50 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 51 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 52 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 53 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 56 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 58 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 60 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 61 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 62 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 63 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 64 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 65 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 70 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 71 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 74 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 75 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 76 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 77 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 78 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 81 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 82 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 83 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 86 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 88 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 90 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 91 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 92 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 93 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 94 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 95 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET
FIGURE 14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022
FIGURE 15 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION)
FIGURE 16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 18 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022
FIGURE 19 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION)
FIGURE 20 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022
FIGURE 23 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022
FIGURE 27 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022)
FIGURE 31 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022)
FIGURE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030)
FIGURE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030)
FIGURE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030)
FIGURE 35 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%)
